Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial

Plus a plant-derived COVID-19 vaccine moves into Phase II/III

Executive Summary

Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.

You may also be interested in...



Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.

Coronavirus Notebook: Pfizer/BioNTech & Russian Vaccines Each Claim Efficacy Of More than 90%

As data start to come in on the first coronavirus vaccines, hopes are rising that vaccination campaigns will be able to begin in the next month or two, although experts have cautioned against unbridled optimism. Uncertainties also remain over questions such as whom to vaccinate first and how to assure equitable access in less wealthy parts of the world.

The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats

Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel